Aerie Pharmaceuticals reported $29.83M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Aerie Pharmaceuticals AERI:US $ 29.84M 84.83M
Alimera Sciences ALIM:US $ 11.9M 2.06M
Amarin AMRN:US $ 94.63M 49.86M
Bluebird Bio BLUE:US $ 1.94M 0.34M
Cara Therapeutics CARA:US $ 4.79M 3.97M
Coherus Biosciences CHRS:US $ 60.12M 13.26M
Endo International Ordinary Shares ENDP:US $ 652.26M 137.17M
Horizon Pharma HZNP:US $ 885.24M 129.22M
Insmed INSM:US $ 53.11M 3.02M
JAZZ PHA JAZZ:US $ 813.72M 83.01M
Merk MRK:US $ 15901M 2380M
Mirati Therapeutics MRTX:US $ 0.71M 0.41M
Novartis NOVN:VX SF 12814M 708M
Pacira Pharmaceuticals PCRX:US $ 157.99M 1.2M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Revance Therapeutics RVNC:US $ 25.26M 0.69M
Supernus Pharmaceuticals SUPN:US $ 152.51M 6.54M
Teva Pharmaceutical Industries TEVA:US $ 3661M 439M
Valeant Pharmaceuticals VRX:CN $ 1918M 278M
Zoetis ZTS:US $ 1986M 19M